Skip to main content
. 2013 Sep 18;33(38):15022–15031. doi: 10.1523/JNEUROSCI.5833-12.2013

Figure 6.

Figure 6.

The chronic treatment with NRG1 impairs iLTD. A, iLTD was induced by a 10 min application of DHPG (50 μm), a group I mGluR agonist. The magnitude of iLTD at 47–52 min in NRG1-treated cells was significantly smaller than that in control cells. *p = 0.008 (t test). B, The iLTD experiments were performed in the presence of JZL184 (0.2 μm) in the extracellular solution. The magnitude of iLTD at 47–52 min in NRG1-treated neurons was not significantly different from the control value. C, An iLTD-induced decrease in 1/PPR3 (PPR3 = third IPSC/first IPSC evoked at 20 Hz), as an indication of relative Pr, was significantly smaller in NRG1-treated cells than in sister control cells. *p = 0.015 (t test). In JZL184, there was no difference in the iLTD-induced decrease in 1/PPR3 between the two groups. D, In control slices (i.e., not treated with NRG1), PPR3 was measured after various periods of JZL184 application at 0.2 or 1 μm. Dashed lines indicate the PPR3 (mean ± SEM) of control slices without JZL184 (replotted from Fig. 5C). *p < 0.005 (Bonferroni t tests vs other data points, including the non-JZL184 control, after ANOVA). Error bars indicate SEM.